Biovie (BIVI) Long-Term Deferred Tax (2014 - 2026)
Biovie (BIVI) posted Long-Term Deferred Tax of $74.9 million for Q2 2025, up 7.61% sequentially from $69.6 million in Q2 2024, and up 7.61% YoY from $69.6 million in Q2 2024.
Biovie (BIVI) Long-Term Deferred Tax (2014 - 2026) Analysis & Trends
Biovie has reported Long-Term Deferred Tax for 7 years, with the latest figure at $74.9 million in Q2 2025.
- Quarterly Long-Term Deferred Tax rose 7.61% year-over-year to $74.9 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $74.9 million (up 7.61% YoY) and the FY2025 annual result came in at $74.9 million, up 7.61% from the prior year.
- Long-Term Deferred Tax improved to $74.9 million in Q2 2025 per BIVI's latest filing, from $69.6 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $74.9 million in Q2 2025 and troughed at $8.0 million in Q2 2022.
- A 4-year average of $53.3 million and a median of $65.1 million in 2023 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2023 and 2025: Long-Term Deferred Tax soared 657.5% in 2023, then gained 7.61% in 2025.
- Over 4 years, Long-Term Deferred Tax stood at $8.0 million in 2022, then jumped by 657.5% to $60.6 million in 2023, then gained by 14.85% to $69.6 million in 2024, then climbed by 7.61% to $74.9 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $74.9 million, $69.6 million, and $60.6 million for Q2 2025, Q2 2024, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82.40 Mn |
| Jun 30, 2025 | 74.90 Mn |
| Jun 30, 2024 | 69.60 Mn |
| Jun 30, 2023 | 60.60 Mn |
| Jun 30, 2022 | 8.00 Mn |
| Jun 30, 2016 | 346,179.00 |
| Mar 31, 2016 | 283,300.00 |
| Dec 31, 2015 | 261,900.00 |
| Sep 30, 2015 | 241,100.00 |
| Jun 30, 2015 | 223,300.00 |
| Mar 31, 2015 | 201,900.00 |
| Dec 31, 2014 | 182,900.00 |
| Sep 30, 2014 | 155,300.00 |
| Jun 30, 2014 | 132,400.00 |
| Mar 31, 2014 | 51,200.00 |